CRDF (Cardiff Oncology) Short Percentage of Float


CRDF Cardiff Oncology Inc CRDF
53 GF Score
Price $1.24
GF Value $1.48
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CRDF vs VTVT, GUTS, BDTX: Short Percentage of Float Comparison

For the Biotechnology subindustry, Cardiff Oncology's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiff Oncology Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Short Percentage of Float falls into.


CRDF
53GF Score
Cardiff Oncology Inc CRDF
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $1.24 is trading 16.2% below its estimated GF Value™ of $1.48. GuruFocus considers Cardiff Oncology to be Modestly Undervalued.

Key valuation signals for CRDF:

  • Short Percentage of Float:
  • GF Value™: $1.48 vs. price of $1.24 (16.2% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
53GF Score

Get the complete analysis for CRDF

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.24
Price
$1.48
GF Value